Private Placement for Arcis Biotechnology
15th December 2010
Zeus Capital, the Manchester-based Corporate Finance advisory firm, has advised on an investment in Arcis Biotechnology and helped it secure additional funding from a network of private investors. Arcis, producers of a suite of environmentally benign cleaning and germ-killing products for a diverse range of markets and applications, is already in discussions with several global companies who are keen to utilise its proprietary technology.
Richard Hughes, Director at Zeus Capital said:
“When Arcis approached us with their Bi-giene product, we saw it as a really exciting opportunity for ourselves and our network of private investors. Bi-giene is going to revolutionise the sector: as well as using green chemistry, it is very long-lasting and extremely efficacious. Bi-giene could soon become the leading brand in the anti-microbial market, and Arcis has the potential to be a leading North West business.”
Leigh Bradley, Managing Director at Arcis Biotechnology added:
“I am delighted that Zeus Capital were able to not only secure funding for Arcis but also assist us in the development of our leadership team and industry contact network. Zeus has a wealth of invaluable experience and contacts in this sector, which will help us break through into a number of very exciting markets for our products.”
Zeus Capital provides financial advice and deal execution expertise on all types of transactions, including flotations, mergers and acquisitions, debt restructuring, private placements and fundraisings in public and private markets. Zeus has a retained financial advisor relationship with a significant number of mid-market AIM listed and privately owned companies.